--- title: "Weekly Recap | BWX Tech -11.73%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/306355830.md" description: "BWX Tech lost 11.73% this week to close at $108.54, while the S&P 500 dropped 8.61%, leaving the stock about 3.12 percentage points behind the benchmark. After opening at $120.04 on Monday, the shares mostly traded between $115 and $122 for the first four sessions. Friday saw a sharper move lower, with the price sliding from $116.27 to an intraday low of $108.17 before settling at $108.54. Weekly amplitude was 11.85%, and average daily volume of around 1." datetime: "2026-11-21T06:20:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306355830.md) - [en](https://longbridge.com/en/news/306355830.md) - [zh-HK](https://longbridge.com/zh-HK/news/306355830.md) generator: "portal-rs" --- # Weekly Recap | BWX Tech -11.73%, consensus target above spot ## The Week BWX Tech lost 11.73% this week to close at $108.54, while the S&P 500 dropped 8.61%, leaving the stock about 3.12 percentage points behind the benchmark. After opening at $120.04 on Monday, the shares mostly traded between $115 and $122 for the first four sessions. Friday saw a sharper move lower, with the price sliding from $116.27 to an intraday low of $108.17 before settling at $108.54. Weekly amplitude was 11.85%, and average daily volume of around 1.71 million shares was well above the recent median. ## Key Events The week’s narrative centred on the Cambridge facility expansion. On 18 November, reports highlighted BWX Technologies’ expansion of its Cambridge plant while noting that the undervalued narrative faced a reality check; the same day’s US research roundup also mentioned the company. On 20 November, another piece asked whether the Cambridge nuclear expansion would change the BWX Tech stock narrative. On 21 November, BWX Technologies fell more than 6% intraday, in line with the softer price action seen over the preceding sessions. ## Analyst Ratings Among 18 institutions covering the stock, 11 rate it buy, 3 rate it overweight and 4 rate it hold, with no sell or underweight ratings. The consensus recommendation is buy, with a consensus target price of $199.19, implying about 83.5% upside from the latest price. Target prices range from $140 to $250, pointing to wide dispersion. The stock ranks 15th among 86 names in its industry. ## The Week Ahead On the macro front, 24 November brings FHFA house prices, the Case-Shiller 20-city index, consumer confidence and the Richmond Fed composite index. Further out, the company’s fiscal Q4 2026 results are scheduled for 22 February 2027, after the market close. ## In Short Institutional coverage skews positive, with 11 buy and 3 overweight ratings and a consensus target of $199.19, roughly 83.5% above spot, but the $140-$250 target range signals meaningful disagreement. The stock accelerated lower this week to $108.54, closing below its 20-day moving average and touching the lowest level of the past 60 sessions. The latest session’s large-lot flow also turned net seller. What matters next is whether upcoming results start to narrow the wide dispersion in analyst targets. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [BWXT.US](https://longbridge.com/en/quote/BWXT.US.md) ## Related News & Research - [Will Cambridge Nuclear Expansion Change BWXT Stock Narrative](https://longbridge.com/en/news/306221996.md) - [BWX Technologies (BWXT) Expands Cambridge Facility As Undervalued Narrative Faces A Reality Check](https://longbridge.com/en/news/305889626.md) - [BWX Technologies secures consent for debt amendments](https://longbridge.com/en/news/305504281.md) - [BWX Technologies Completes CAD 80 Million Cambridge Manufacturing Expansion](https://longbridge.com/en/news/305318830.md) - [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**